AZR-MD-001 + sodium hyaluronate

AZR-MD-001 + sodium hyaluronate is a **combination ophthalmic therapy** in development for the treatment of Meibomian Gland Dysfunction (MGD) and associated ocular surface diseases. The core component, AZR-MD-001, is a **selenium sulfide-based ointment** designed for application to the lower eyelid. **Sodium hyaluronate** (marketed as Hylo-Forte), a lubricant and hydrating agent, is administered prior to the ointment. The combination is hypothesized to improve the safety and tolerability of selenium sulfide therapy, as well as to provide additional moisturizing and symptomatic relief. The mechanism of AZR-MD-001 involves breaking down abnormal keratin in the glands to soften existing blockages, slowing keratin production to prevent new blockages, increasing quality and quantity of meibum secretion, and may have antimicrobial effects. Sodium hyaluronate provides lubrication, stabilizes the tear film, and improves comfort for patients receiving ocular ointment treatment[1][2][3][4][5][6][7].

Brand names

AZR-MD-001AZR-MD001AZR-MD 001Hylo-Forte

Other names

selenium sulfide ophthalmic ointment + sodium hyaluronateAZR-MD-001 + Hylo-Forte